A new cooling pad enters the healthcare market, joining a growing number of cooling systems used to induce hypothermia ...

Healthcare IT companies will again converge this winter to measure their ability to integrate with each other during the ...

Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...

The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory ...

British researchers have concluded that counseling and education aimed at preventing coronary heart disease have no impact on mortality and little effect in terms of clinical events, reports “heartwire.” Dr Shah Ebrahim (London School of Tropical Medicine, UK) and colleagues report their findings in the Oct. 18, 2006 Cochrane Database of Systematic Reviews.

TeraRecon Inc. and Commissure, Inc. have announced a partnership to integrate and deliver seamless workflow ...

Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

A stent designed to dissolve after it completes its task of propping open narrowed heart arteries is being tested by scientists. The first human experiment with the dissolving stent is being conducted with 26 patients at hospitals in New Zealand and Europe, the Associated Press reported. The study is designed to test whether the stent is safe enough to be used in larger studies.